A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Our Company We are a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. On July 3, 2025, the U.S. Food and Drug Administration (the “FDA”) approved our new drug application (“NDA”) for the use of EKTERLY® (sebetralstat), a novel, orally delivered, small molecule plasma kallikrein inhibitor, for the treatment of acute attacks of hereditary angioedema (“HAE”) in adult and pediatric patients aged 12 years and older. EKTERLY (sebetralstat) is the first and only oral, on-demand therapy for HAE. The efficacy and safety of EKTERLY was established by the results from the phase 3 KONFIDENT clinical trial, published in the New England Journal of Medicine in May 2024.
| Metric | TTM | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | 16M | 8.4M | - | 2.1M |
| Net Income | -260M | -29M | -21M | -16M | -19M | - |
| EPS | $-4.88 | $-1.64 | $-1.38 | $-1.53 | $-4.47 | $-26.17 |
| Free Cash Flow | -202M | -45M | -37M | 9.1M | -24M | -13M |
| ROIC | -58.7% | -34.8% | -21.5% | -57.9% | -59.4% | - |
| Gross Margin | - | - | - | - | - | 0.0% |
| Debt/Equity | 8.18 | 0.10 | 0.22 | 0.01 | 0.10 | -1.67 |
| Dividends/Share | $0.00 | - | - | - | - | $0.00 |
| Operating Income | -253M | -41M | -30M | -19M | -22M | -15M |
| Operating Margin | 0.0% | - | -184.9% | -222.8% | - | -711.7% |
| ROE | -1527.4% | -34.8% | -21.5% | -58.0% | -59.4% | - |
| Shares Outstanding | 51M | 18M | 15M | 10M | 11M | 10M |
| Metric | 2014 | 2015 | 2016 | 2017 | 2018 | |||
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 29K | N/A | 2.1M | N/A | 8.4M | 16M | N/A | 0 |
| Gross Margin | 0.0% | 0.0% | 0.0% | N/A | N/A | N/A | N/A | N/A |
| R&D | 8.3M | 16M | 15M | 13M | 18M | 35M | 40M | 70M |
| SG&A | 3.4M | 4.9M | 2.7M | 11M | 8.9M | 11M | 13M | 195M |
| EBIT | -12M | -21M | -15M | -22M | -19M | -30M | -41M | -253M |
| Op. Margin | -40265.5% | N/A | -711.7% | N/A | -222.8% | -184.9% | N/A | 0.0% |
| Net Income | N/A | -25M | N/A | -19M | -16M | -21M | -29M | -260M |
| Net Margin | N/A | N/A | N/A | N/A | -188.3% | -129.1% | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||
| ROIC | N/A | -47.4% | N/A | -59.4% | -57.9% | -21.5% | -34.8% | -58.7% |
| ROE | N/A | -968.8% | N/A | -59.4% | -58.0% | -21.5% | -34.8% | -1527.4% |
| ROA | N/A | -78.3% | N/A | -54.2% | -25.7% | -17.6% | -31.5% | -76.4% |
| Cash Flow | ||||||||
| Op. Cash Flow | -11M | -21M | -13M | -24M | 11M | -36M | -45M | -200M |
| Free Cash Flow | -11M | -22M | -13M | -24M | 9.1M | -37M | -45M | -202M |
| Owner Earnings | -12M | -22M | -13M | -24M | 9.3M | -40M | -50M | -220M |
| CapEx | 159K | 659K | 11K | 74K | 1.4M | 1.1M | 220K | 2.2M |
| Maint. CapEx | 54K | 133K | 33K | 40K | 180K | 378K | 512K | 1.4M |
| Growth CapEx | 105K | 526K | 0 | 34K | 1.2M | 703K | 0 | 811K |
| D&A | 54K | 133K | 33K | 40K | 180K | 378K | 512K | 1.4M |
| CapEx/OCF | N/A | N/A | N/A | N/A | 13.5% | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 381K | 785K | 118K | 394K | 1.1M | 3.0M | 4.4M | 18M |
| Debt Repayment | 708K | 708K | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||
| Net Debt | -1.2M | -103M | N/A | N/A | -102M | N/A | N/A | -170M |
| Cash & Equiv. | 3.9M | 54M | 22M | 31M | 51M | 32M | 16M | 309M |
| Long-Term Debt | 2.1M | 3.2M | N/A | N/A | 58K | N/A | N/A | 139M |
| Debt/Equity | -0.15 | 0.09 | -1.67 | 0.10 | 0.01 | 0.22 | 0.10 | 8.18 |
| Interest Coverage | -10.8 | -17.7 | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | -44M | 49M | -37M | 31M | 27M | 97M | 84M | 17M |
| Total Assets | 6.6M | 57M | 25M | 34M | 61M | 118M | 93M | 340M |
| Total Liabilities | 51M | 7.5M | 62M | 3.0M | 34M | 21M | 8.8M | 323M |
| Intangibles | 0 | 0 | 0 | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -48M | -73M | -37M | -56M | -72M | -92M | -122M | -739M |
| Working Capital | -2.5M | 51M | 21M | 31M | 36M | 97M | 81M | 280M |
| Current Assets | 4.6M | 55M | 25M | 34M | 59M | 116M | 89M | 325M |
| Current Liabilities | 7.1M | 4.3M | 3.2M | 3.0M | 23M | 18M | 7.7M | 45M |
| Per Share Data | ||||||||
| EPS | -305.34 | -18.20 | -26.17 | -4.47 | -1.53 | -1.38 | -1.64 | -4.88 |
| Owner EPS | -6.21 | -15.95 | -1.37 | -2.24 | 0.90 | -2.63 | -2.80 | -4.35 |
| Book Value | -23.49 | 36.12 | -3.82 | 2.90 | 2.64 | 6.41 | 4.72 | 0.34 |
| Cash Flow/Share | -5.98 | -15.28 | -1.35 | -2.20 | 1.02 | -2.41 | -2.52 | -5.11 |
| Dividends/Share | 0.00 | 0.00 | 0.00 | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 1.9M | 1.4M | 9.7M | 10.8M | 10.3M | 15.1M | 17.8M | 50.5M |
| Valuation | ||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -4.0 |
| P/FCF | N/A | N/A | N/A | N/A | 10.7 | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | 1.0 | 3.6 | 3.5 | 2.4 | 58.3 |
| Price/Sales | N/A | N/A | N/A | N/A | 11.0 | 16.2 | N/A | N/A |
| FCF Yield | N/A | N/A | N/A | -76.3% | 9.4% | -11.1% | -22.9% | -20.4% |
| Market Cap | 0 | 0 | 0 | 31M | 97M | 336M | 197M | 990M |
| Avg. Price | 0.00 | 0.00 | 0.00 | 8.36 | 8.96 | 17.33 | 15.23 | 19.59 |
| Year-End Price | 0.00 | 0.00 | 0.00 | 7.49 | 9.43 | 22.30 | 11.09 | 19.59 |
KalVista Pharmaceuticals, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
KalVista Pharmaceuticals, Inc. (KALV) has a 5-year average return on invested capital (ROIC) of -43.4%. This is below average and may indicate limited pricing power.
KalVista Pharmaceuticals, Inc. (KALV) has a market capitalization of $990M. It is classified as a small-cap stock.
KalVista Pharmaceuticals, Inc. (KALV) does not currently pay a regular dividend.
KalVista Pharmaceuticals, Inc. (KALV) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
KalVista Pharmaceuticals, Inc. (KALV) generated $-45 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
KalVista Pharmaceuticals, Inc. (KALV) has a debt-to-equity ratio of 0.10. This indicates a conservatively financed balance sheet.
KalVista Pharmaceuticals, Inc. (KALV) reported earnings per share (EPS) of $-1.64 in its most recent fiscal year.
KalVista Pharmaceuticals, Inc. (KALV) has a return on equity (ROE) of -34.8%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 7 years of financial data for KalVista Pharmaceuticals, Inc. (KALV), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
KalVista Pharmaceuticals, Inc. (KALV) has a book value per share of $4.72, based on its most recent annual SEC filing.